Concepedia

Author

Janet Schnee

Boehringer Ingelheim (Germany)ORCID

Also Known As

J M Schnee, J SCHNEE, J Schnee, J. SCHNEE, J. Schnee, J.M. Schnee, Janet M. Schnee, Janet Schnee, Kathy Fraeman, Stefan Hantel

56

Publications

17.4K

Citations

25

H-Index

58

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (United States)French Clinical Research Infrastructure NetworkSahlgrenska University HospitalNational and Kapodistrian University of Athens
JS

About

Janet Schnee is an author at Boehringer Ingelheim (Germany) specializing in medicine, orthopaedics, and thrombosis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

12

2.7K

2

Biology

3

3

143

3

Natural Sciences

2

2

125

4

Engineering

1

1

91

5

Health Sciences

1

1

1.1K

Janet Schnee

×

31

Publications

16.4K

Citations

23

H-Index

YearCitations

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer, Stefan D. Anker, Javed Butler,

New England Journal of Medicine

2020

4.7K

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker, Javed Butler, Gerasimos Filippatos,

New England Journal of Medicine

2021

4.3K

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

Sam Schulman, Clive Kearon, Ajay K. Kakkar,

New England Journal of Medicine

2009

2.5K

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial

Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher,

The Lancet

2007

1.1K

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

Bengt I. Eriksson, O.E. Dahl, Nadia Rosencher,

Journal of Thrombosis and Haemostasis

2007

983

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

Ola Dahl, Michael H. Huo, Andreas Kurth,

Thrombosis and Haemostasis

2011

398

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

Milton Packer, Javed Butler, Faı̈ez Zannad,

Circulation

2021

332

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function

Faı̈ez Zannad, João Pedro Ferreira, Stuart Pocock,

Circulation

2020

262

Evaluation of the Effects of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved Trial

Stefan D. Anker, Javed Butler, Gerasimos Filippatos,

European Journal of Heart Failure

2019

248

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

Javed Butler, Milton Packer, Gerasimos Filippatos,

European Heart Journal

2021

243

Page 1